Document is current

Article History

Received: 23 February 2025

Accepted: 15 April 2025

First Online: 4 May 2025

Declarations

:

: Marwan N. Sabbagh has stock or stock options in NeuroTau, uMethod Health, Versanum, Athira, TransDermix, Seq BioMarque, NeuroReserve, Cortexyme/Quince Therapeutics, Lighthouse Therapeutics. Marwan N. Sabbagh is a consultant for Alzheon, Biogen, Roche-Genentech, Eisai Inc., KeifeRx, Lilly, Synaptogenix, NeuroTherapia, T3D, Signant Health, Novo Nordisk. Marwan N. Sabbagh receives royalties from Humanix. Marwan N. Sabbagh is a Board of Director for EIP Pharma. Marwan N. Sabbagh is Editor in Chief of Neurology and Therapy. Marwan N. Sabbagh was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Kavita V. Nair is a consultant/and has received an honorarium from Eisai, Inc., Sanofi, Genentech, TG Therapeutics, AstraZeneca, Alnylam, Amgen, Alzheon, MJH Lifesciences, American Academy of Neurology, ICER and Applied Patient Experience. Chenyue Zhao, Feride Frech, Se Ryeong Jang, and Hideki Toyosaki are employees of Eisai Inc. Malena Mahendran, Kaixin Zhang, and François Laliberté are employees of Group d’analyse, SRI, a consulting company that has provided paid consulting services to Eisai Inc. and Biogen Inc., which funded the development and conduct of this study and short communication.

: The study was considered exempt research under 45 CFR § 46.104(d)(4) as it involved only the secondary use of data that were de-identified in compliance with the Health Insurance Portability and Accountability Act (HIPAA), specifically, 45 CFR § 164.514. The data used for this analysis were provided with permission and under license from Komodo Health.